...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature clinical practice. Oncology >Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.
【24h】

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.

机译：溶瘤病毒疗法的临床试验结果：一个有希望的世纪，一个十年的进步。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Therapeutic oncolytic viruses (virotherapeutics) constitute a novel class of targeted anticancer agents that have unique mechanisms of action compared with other cancer therapeutics. The development of virotherapeutics has evolved from the use of in vitro-passaged strains (first generation), to genetically engineered selectivity-enhanced viruses (second generation) and finally to genetically engineered transgene-expressing 'armed' oncolytic viruses (third generation). Descriptions of cancer remissions following virus infections date back to a century ago. Initial patient treatment publications, written up to 50 years ago, consisted of case reports or case series of treatment with first-generation, non-engineered viruses. Over the past decade, hundreds of patients with cancer have been treated on prospectively designed clinical trials (including phase III), evaluating over 10 different agents, inlcluding engineered second-generation and third-generation viruses. This Review summarizes and interprets thedata from clinical reports over the last century, including safety, efficacy and biological end points (viral and immunologic). Systemic safety and efficiacy has been clearly demonstrated with some virotherapeutics. The implications of these data for future virotherapy development are discussed.
机译：治疗性溶瘤病毒（病毒治疗剂）构成了一类新型的靶向抗癌剂，与其他癌症治疗剂相比，它们具有独特的作用机制。病毒治疗学的发展已从使用体外传代菌株（第一代）发展到基因工程选择性增强病毒（第二代），最后发展到基因工程表达转基因的“武装”溶瘤病毒（第三代）。关于病毒感染后癌症缓解的描述可追溯到一个世纪前。最初的患者治疗出版物可以追溯到50年前，包括第一代非工程病毒治疗的病例报告或病例系列。在过去的十年中，已经通过前瞻性设计的临床试验（包括III期）治疗了数百名癌症患者，评估了10多种不同的药物，包括工程化的第二代和第三代病毒。这篇综述总结和解释了上个世纪临床报告中的数据，包括安全性，功效和生物学终点（病毒和免疫学）。系统的安全性和有效性已通过某些病毒疗法得到了明确证明。讨论了这些数据对未来病毒疗法发展的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号